Market Research Report
Investigation Report on Chinese Clopidogrel Market 2021-2025
|Published by||China Research and Intelligence||Product code||1002613|
|Published||Content info||50 Pages
Delivery time: 1-2 business days
|Investigation Report on Chinese Clopidogrel Market 2021-2025|
|Published: April 23, 2021||Content info: 50 Pages||
Clopidogrel is a medication that inhibits platelet aggregation and is mainly used to prevent atherosclerotic thrombosis. The original drug, Plavix, is developed by Sanofi. It enters the Chinese market in 2001. In addition to Sanofi, the other main manufacturers of Clopidogrel in the Chinese market are Salubris Pharmaceuticals, Lepu Pharmaceutical, and CSPC Ouyi Pharmaceutical.
According to CRI's market research, the sales revenue of Clopidogrel in China has been decreasing since 2018, the sales value of Clopidogrel in China was approximately CNY680 million, and the CAGR is -21.9% in 2016 to 2020. The decrease in sales is mainly due to the impact of centralized procurement and the appearance of alternative drugs. Nevertheless, as the antithrombotic market keeps expanding, Clopidogrel will still have considerable annual sales in the short term. In addition, the price of Clopidogrel has been greatly reduced because of centralized procurement. Thus, some people may be more willing to choose Clopidogrel instead of other biosimilar drugs. CRI concludes that as the epidemic situation improves, Clopidogrel sales in China is expected to have a restorative growth, and it will also become more stable from 2022 to 2025.